Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
458 studies found for:    multiple myeloma | Open Studies | multiple myeloma
Show Display Options
Rank Status Study
21 Recruiting A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Condition: Multiple Myeloma
Intervention: Drug: IMNOVID
22 Recruiting Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
Condition: Multiple Myeloma
Intervention:
23 Recruiting A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: PAD;   Drug: VCD;   Other: ASCT
24 Recruiting A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD);   Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab;   Drug: Daratumumab
25 Recruiting Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
26 Recruiting Multiple Myeloma Minimal Residual Disease
Condition: Multiple Myeloma
Intervention: Biological: blood samples and bone marrow aspirates will be collected
27 Recruiting Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ABBV-838;   Drug: Pomalidomide;   Drug: Dexamethasone
28 Recruiting Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Daratumumab
29 Recruiting Institut Paoli Calmettes Multiple Myeloma Database
Condition: Multiple Myeloma
Intervention: Other: Data collection
30 Recruiting Autologous Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
31 Available Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma
Interventions: Drug: Ulocuplumab;   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
32 Recruiting Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Oprozomib formulation 1;   Drug: Oprozomib formulation 2;   Drug: Dexamethasone;   Drug: Pomalidomide
33 Recruiting Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Clarithromycin;   Drug: Thalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
34 Recruiting Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Condition: Multiple Myeloma
Interventions: Procedure: Tumor Cell Collection;   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Procedure: Leukapheresis;   Biological: Myeloma vaccine;   Drug: GM-CSF;   Drug: Lenalidomide
35 Available Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Daratumumab
36 Recruiting Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
37 Not yet recruiting A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Dexamethasone
38 Recruiting Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plitidepsin;   Drug: Bortezomib;   Drug: Dexamethasone
39 Recruiting Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
40 Recruiting A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Condition: Smoldering Multiple Myeloma
Interventions: Drug: Nivolumab;   Drug: Lenalidomide;   Drug: Dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.